Autobahn Therapeutics, Inc.
Clinical trials sponsored by Autobahn Therapeutics, Inc., explained in plain language.
-
New hope for bipolar depression? drug ABX-002 enters Mid-Stage trial
Symptom relief Recruiting nowThis study tests whether adding ABX-002 to existing treatments can improve depression symptoms in adults with bipolar disorder. About 30 participants will take the drug for 6 weeks, and some will have brain scans to see how it affects brain chemistry. The goal is to find a better…
Phase: PHASE2 • Sponsor: Autobahn Therapeutics, Inc. • Aim: Symptom relief
Last updated May 17, 2026 07:21 UTC
-
New depression pill shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests whether adding ABX-002 to current antidepressant medication can improve depression symptoms in adults with moderate to severe major depressive disorder who haven't responded well enough to their existing treatment. About 230 participants will be randomly assigned…
Phase: PHASE2 • Sponsor: Autobahn Therapeutics, Inc. • Aim: Symptom relief
Last updated May 17, 2026 06:52 UTC